114 related articles for article (PubMed ID: 7274344)
1. De novo pyrimidine nucleotide synthesis in the preimplantation mouse embryo.
Troike DE; Brinster RL
Exp Cell Res; 1981 Aug; 134(2):481-4. PubMed ID: 7274344
[No Abstract] [Full Text] [Related]
2. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Moyer JD; Handschumacher RE
Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
[No Abstract] [Full Text] [Related]
3. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
4. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
5. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
Laval M; Azou Y; Giorgi D; Rosset R
Exp Cell Res; 1986 Apr; 163(2):381-95. PubMed ID: 2869965
[TBL] [Abstract][Full Text] [Related]
6. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
[TBL] [Abstract][Full Text] [Related]
7. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Karle JM; Cowan KH; Chisena CA; Cysyk RL
Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477
[TBL] [Abstract][Full Text] [Related]
8. Salvage of circulating pyrimidine nucleosides in the rat.
Moyer JD; Oliver JT; Handschumacher RE
Cancer Res; 1981 Aug; 41(8):3010-7. PubMed ID: 7248957
[TBL] [Abstract][Full Text] [Related]
9. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
10. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells.
Karle JM; Anderson LW; Cysyk RL
J Biol Chem; 1984 Jan; 259(1):67-72. PubMed ID: 6323418
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
13. Effect of uridine on de novo pyrimidine biosynthesis in rat hepatoma cells in culture.
Hoogenraad NJ; Lee DC
J Biol Chem; 1974 May; 249(9):2763-8. PubMed ID: 4364029
[No Abstract] [Full Text] [Related]
14. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
Loh E; Kufe DW
Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.
Eldo J; Heng S; Kantrowitz ER
Bioorg Med Chem Lett; 2007 Apr; 17(7):2086-90. PubMed ID: 17336518
[TBL] [Abstract][Full Text] [Related]
16. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
Swyryd EA; Seaver SS; Stark GR
J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
[No Abstract] [Full Text] [Related]
17. Pyrimidine biosynthesis in Plasmodium berghei.
Hill B; Kilsby J; McIntosh RT; Wrigglesworth R; Ginger CD
Int J Biochem; 1981; 13(3):303-10. PubMed ID: 6260538
[No Abstract] [Full Text] [Related]
18. Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool.
Katsafanas GC; Grem JL; Blough HA; Moss B
Virology; 1997 Sep; 236(1):177-87. PubMed ID: 9299630
[TBL] [Abstract][Full Text] [Related]
19. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
Karle JM; Anderson LW; Dietrick DD; Cysyk RL
Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
